|
1
|
Guggenheim DE and Shah MA: Gastric cancer
epidemiology and risk factors. J Surg Oncol. 107:230–236. 2013.
View Article : Google Scholar
|
|
2
|
Krejs GJ: Gastric cancer: Epidemiology and
risk factors. Dig Dis. 28:600–603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allan AL, Vantyghem SA, Tuck AB and
Chambers AF: Tumor dormancy and cancer stem cells: Implications for
the biology and treatment of breast cancer metastasis. Breast Dis.
26:87–98. 2007.PubMed/NCBI
|
|
4
|
Brábek J, Mierke CT, Rösel D, Veselý P and
Fabry B: The role of the tissue microenvironment in the regulation
of cancer cell motility and invasion. Cell Commun Signal. 8:222010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kiechle FLand Zhang X: Apoptosis:
biochemical aspects and clinical implications. Clin Chim Acta.
326:27–45. 2002. View Article : Google Scholar
|
|
7
|
Schultz DR and Harrington WJ Jr:
Apoptosis: Programmed cell death at a molecular level. Semin
Arthritis Rheum. 32:345–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Llambi F and Green DR: Apoptosis and
oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet
Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weyhenmeyer B, Murphy AC, Prehn JH and
Murphy BM: Targeting the anti-apoptotic Bcl-2 family members for
the treatment of cancer. Exp Oncol. 34:192–199. 2012.PubMed/NCBI
|
|
11
|
Davids MS and Letai A: Targeting the
B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol.
30:3127–3135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas LW, Lam C and Edwards SW: Mcl-1;
the molecular regulation of protein function. FEBS Lett.
584:2981–2989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akgul C: Mcl-1 is a potential therapeutic
target in multiple types of cancer. Cell Mol Life Sci.
66:1326–1336. 2009. View Article : Google Scholar
|
|
14
|
Quinn BA, Dash R, Azab B, et al: Targeting
Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs.
20:1397–1411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang T, Zhao C, Luo L, Zhao H, Cheng J
and Xu F: The expression of Mcl-1 in human cervical cancer and its
clinical significance. Med Oncol. 29:1985–1991. 2012. View Article : Google Scholar
|
|
16
|
Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao
Y, Lv Y and Song Y: MiR-101 and Mcl-1 in non-small-cell lung
cancer: Expression profile and clinical significance. Med Oncol.
29:1681–1686. 2012. View Article : Google Scholar
|
|
17
|
Henderson-Jackson EB, Helm J, Ghayouri M,
Hakam A, Nasir A, Leon M, Bui M, Yeatman T and Coppola D:
Correlation between Mcl-1 and pAKT protein expression in colorectal
cancer. Int J Clin Exp Pathol. 3:768–774. 2010.PubMed/NCBI
|
|
18
|
Likui W, Qun L, Wanqing Z, Haifeng S,
Fangqiu L and Xiaojun L: Prognostic role of myeloid cell leukemia-1
protein (Mcl-1) expression in human gastric cancer. J Surg Oncol.
100:396–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maeta Y, Tsujitani S, Matsumoto S, et al:
Expression of Mcl-1 and p53 proteins predicts the survival of
patients with T3 gastric carcinoma. Gastric Cancer. 7:78–84. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsujitani S, Saito H, Wakatsuki T,
Ikeguchi M, Shirabe K, Morita M, Kakeji Y, Yano T and Maehara Y:
Relationship between expression of apoptosis-related proteins and
the efficacy of postoperative chemotherapy in patients with T3
gastric cancer. Surg Today. 42:225–232. 2012. View Article : Google Scholar
|
|
21
|
Akagi H, Higuchi H, Sumimoto H, et al:
Suppression of myeloid cell leukemia-1 (Mcl-1) enhances
chemotherapy-associated apoptosis in gastric cancer cells. Gastric
Cancer. 16:100–110. 2013. View Article : Google Scholar
|
|
22
|
Mandelin AM II and Pope RM: Myeloid cell
leukemia-1 as a therapeutic target. Expert Opin Ther Targets.
11:363–373. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perciavalle RM and Opferman JT: Delving
deeper: MCL-1’s contributions to normal and cancer biology. Trends
Cell Biol. 23:22–29. 2013. View Article : Google Scholar
|
|
24
|
Hartman ML and Czyz M: Anti-apoptotic
proteins on guard of melanoma cell survival. Cancer Lett.
331:24–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bose P and Grant S: Mcl-1 as a therapeutic
target in acute myelogenous leukemia (AML). Leuk Res Rep. 2:12–14.
2013.PubMed/NCBI
|
|
26
|
Frederick L, Greene D and Irvin D: AJCC
cancer staging manual. 6th edition. Springer-Verlag; New York: pp.
17–57. 2002
|
|
27
|
Obexer P and Ausserlechner MJ: X-linked
inhibitor of apoptosis protein - a critical death resistance
regulator and therapeutic target for personalized cancer therapy.
Front Oncol. 4:1972014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Almagro MC and Vucic D: The inhibitor
of apoptosis (IAP) proteins are critical regulators of signaling
pathways and targets for anti-cancer therapy. Exp Oncol.
34:200–211. 2012.PubMed/NCBI
|
|
29
|
Kilbride SM and Prehn JH: Central roles of
apoptotic proteins in mitochondrial function. Oncogene.
32:2703–2711. 2013. View Article : Google Scholar
|
|
30
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
31
|
Soták M, Sumová A and Pácha J: Cross-talk
between the circadian clock and the cell cycle in cancer. Ann Med.
46:221–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fisher D, Krasinska L, Coudreuse D and
Novák B: Phosphorylation network dynamics in the control of cell
cycle transitions. J Cell Sci. 125:4703–4711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu HG, Ai YW, Yu LL, et al:
Phosphoinositide 3-kinase/Akt pathway plays an important role in
chemoresistance of gastric cancer cells against etoposide and
doxorubicin induced cell death. Int J Cancer. 122:433–443. 2008.
View Article : Google Scholar
|
|
34
|
Choi IJ, Kim JS, Kim JM, Jung HC and Song
IS: Effect of inhibition of extracellular signal-regulated kinase 1
and 2 pathway on apoptosis and bcl-2 expression in Helicobacter
pylori-infected AGS cells. Infect Immun. 71:830–837. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McCubrey JA, Steelman LS, Bertrand FE, et
al: GSK-3 as potential target for therapeutic intervention in
cancer. Oncotarget. 5:2881–2911. 2014.PubMed/NCBI
|
|
36
|
Amoyel M, Anderson AM and Bach EA:
JAK/STAT pathway dysregulation in tumors: A Drosophila perspective.
Semin Cell Dev Biol. 28:96–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wacheck V, Cejka D, Sieghart W, Losert D,
Strommer S, Crevenna R, Monia BP and Selzer E: Mcl-1 is a relevant
molecular target for antisense oligonucleotide strategies in
gastric cancer cells. Cancer Biol Ther. 5:1348–1354. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zangemeister-Wittke U and Huwiler A:
Antisense targeting of Mcl-1 has therapeutic potential in gastric
cancer. Cancer Biol Ther. 5:1355–1356. 2006. View Article : Google Scholar : PubMed/NCBI
|
